ST 1898 - Beijing Scitech-Mq Pharmaceuticals
Alternative Names: ST-1898 - Beijing Scitech-Mq PharmaceuticalsLatest Information Update: 22 Dec 2023
At a glance
- Originator Beijing Scitech-Mq Pharmaceuticals
- Class Antineoplastics; Retinoids; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Thyroid cancer
- Phase I/II Malignant melanoma; Renal cell carcinoma
Most Recent Events
- 15 Nov 2023 Phase-II clinical trials in Thyroid cancer (Late-stage disease, Metastatic disease, Second-line or greater) (PO) in China (NCT06359847)
- 07 Nov 2023 Phase-I/II clinical trials in Malignant melanoma (Monotherapy) in China (PO) (NCT06359860)
- 08 May 2023 NMPA accepts IND of ST 1898 for solid tumors